Sirona Biochem attends the Dose of the Valley Conference, San Francisco
– Momentum Public Relations –
Sirona Biochem (SBM:tsxv), an emerging biochemistry company based in Vancouver, B.C., was invited for the second time by the consulate general of Canada in San Francisco to present at the annual Dose of the Valley Conference. The invite-only event took place on February 9-10, 2016 in San Francisco, California.
Sirona Biochem had the unique opportunity to showcase its proprietary platform technology, as well as its diabetes and anti-aging assets to international key players to the likes of l’Oreal, Merck and Johnson & Johnson. During the event, they participated in facilitated meetings, follow up discussions and received feedback from investors. Most importantly, the exclusive event offered many potential partnering opportunities.
Needless to say, this was a cruicial event for Sirona Biochem as their products could bring value to big pharma companies around the world. “Sirona has an innovative platform technology that can be applied to develop new compounds in areas of unmet needs, and we have already begun to explore strategic partnerships with big pharma to unlock the potential value in new opportunities,” said Attila Hajdu, Sirona Biochem’s Chief Business Development Officer, prior to the conference.
Dose of the Valley Conference, San Francisco
The Dose of the Valley conference is a two-day event put together by the C100, BDC Venture Capital, and the Consulate General of Canada in San Francisco. The prestigious event offers the exclusive opportunity to connect a select few of Canada’s most promising life science companies from the biopharmaceutical, medical device and health IT sectors with key players in the Bay Area and Silicon Valley.
San Francisco and more specifically, Silicon Valley is an international hub for flourishing companies in the life sciences sector. A large handful of pharmaceutical companies, medical providers, venture capital, and technology companies have settled in the region, which holds infinite opportunities for Canadian companies such as Sirona Biochem. “The criteria for selection were evaluated on stage of development and industry validation, so we are excited to participate in such a focused event,” added Hajdu. In addition, applications to attend were based on relevancy to industry interests. A few other companies selected to attend were Zucara Therapeutics and the Commercialization for Research Institute in Immunology and Cancer (IRICoR).
The Dose of the Valley Conference was held on February 9-10 in San Francisco, California, and facilitated face-to-face meetings with potential investors, technology scouts, mentors and other industry experts. In attending, Sirona Biochem hoped to gain visibility and develop new partnerships. Sirona’s Chief Business Development Officer Attila Hajdu presented the Company’s pipeline and future strategy at the conference. Hajdu also participated in follow up meetings with key investors and leading companies in the pharmaceutical and cosmetic industries.
About Sirona Biochem
Founded in 2009, Sirona Biochem is a Vancouver based ingredient and drug discovery company dealing with proprietary innovative platform technology of fluorination chemistry. In 2011, the company acquired TF Chem for their chemistry technology and expertise. They develop safer, more effective cosmetic and pharmaceutical active ingredients that are licensed to various partners in exchange for upfront milestone and royalty payments.
The company has recently made headlines as they are currently in discussions with five of the largest pharmaceutical companies in the world about licensing their new skin-lightening technology. This represents a major deal for Sirona, which has a market cap of just over $30 million. For additional information visit www.sironabiochem.com, we have also included their corporate video presentation below.